(Q35142087)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Stephen R. Wisniewski

series ordinal

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

11

David J Kupfer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

7

Frederic M Quitkin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

3

Madhukar H Trivedi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

5

Michael E Thase

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

10

Jerrold F Rosenbaum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

4

Andrew A Nierenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1

Maurizio Fava

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

6

Harold A Sackeim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Philip W Lavori

series ordinal

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

Psychiatric Clinics of North America

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

457-94, x

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

Definition and epidemiology of treatment-resistant depression

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Predictors of persistent social impairment among recovered depressed outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Recovery, chronicity, and levels of psychopathology in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Results of the DSM-IV mood disorders field trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Refractory Depression: Relevance of Psychosocial Factors and Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Health care costs of primary care patients with recognized depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The clinical course of unipolar major depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Pharmacy-enforced outpatient drug treatment protocols: a case study of Medi-Cal restrictions for cefaclor.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Short-Term Psychotherapy of Depressive Disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Subaffective Disorders: Dysthymic, Cyclothymic and Bipolar II Disorders in the “;Borderline” Realm

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

General health, health care utilization, and medical comorbidity in dysthymia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Psychiatrists' responses to failure of maintenance therapy with antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Three-year outcomes for maintenance therapies in recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

". . . and a small dose of an antidepressant might help"

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Antidepressants may not assist recovery in practice: a naturalistic prospective survey

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A study of the use of antidepressant medication in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Treatment Received by Depressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Drug Treatment of Depressed Patients Referred for Hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A multiple-dose, controlled study of phenelzine in depression-anxiety states.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Two dosages of imipramine in hospitalized endogenous and neurotic depressives

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Clinical and pharmacokinetic factors affecting response to phenelzine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Metabolism, anticholinergic effects, and therapeutic outcome of desmethylimipramine in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Dose-response relationship with venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Refractory depression: the addition of lithium to fluoxetine or desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The benefit of lithium carbonate adjunct in refractory depression--fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Novel uses of thyroid hormones in patients with affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Buspirone augmentation of antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Paroxetine/bupropion combination treatment for refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Bupropion and sertraline combination treatment in refractory depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Mirtazapine augmentation in the treatment of refractory depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Monoamines and abnormal behaviour. A multi-aminergic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Danish University Antidepressant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Fluoxetine in tricyclic refractory major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Citalopram treatment of fluoxetine nonresponders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Prevention of relapse in residual depression by cognitive therapy: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A Structured Interview Guide for the Hamilton Depression Rating Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The inventory for depressive symptomatology (IDS): Preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Clinical quality measurement. Comparing chart review and automated methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Patient-proxy response comparability on measures of patient health and functional status.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Strengthening clinical effectiveness trials: equipoise-stratified randomization.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Identification of patient attitudes and preferences regarding treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

'Adherence' and the Negotiated Approach to Patienthood

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

National Institute of Mental Health Treatment of Depression Collaborative Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Declaration of treatment failures

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Duration of antidepressant drug treatment. What is an adequate trial?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Time course of improvement under antidepressant treatment: a survival-analytical approach

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Changing physician performance. A systematic review of the effect of continuing medical education strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Computerized algorithms and pediatricians' management of common problems in a community clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Delayed feedback of physician performance versus immediate reminders to perform preventive care. Effects on physician compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Algorithm based improvement of clinical quality

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

An active set algorithm for treatment planning optimization.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

A decision analysis of practice patterns used in evaluating and treating abnormal Pap smears.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

Developing policies and guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900107-7

7 January 2021

10.1016/S0193-953X(02)00107-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12778843%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference